Moleculin Biotech awards Cermak 4,000 stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Moleculin Biotech, Inc. director Elizabeth Cermak received 4,000 stock options as an award for Board service, with an exercise price of $6.83 per share and an expiration date of November 17, 2036. The options vest on the earlier of November 17, 2027, or the date of the company’s next annual meeting, subject to continued Board service. The reported option-related position after the award was 4,331 shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) F2, F1 | 4,000 | -- | -- |
Footnotes (2)
- F1. The options set forth in this table vest on the earlier of November 17, 2027 or the date of the Company's next annual meeting of shareholders, subject to the grantee's continued service on the Company's Board of Directors on the vesting date.
- F2. The options were issued in connection with the reporting person's Board of Director service to the Company.
Key Figures
Key Terms
Stock Options (right to buy) financial
vest financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many stock options did MBRX director Elizabeth Cermak receive?
When do Elizabeth Cermak’s MBRX options vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.